Risk of tuberculosis in patients treated with anti‐tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 18, Iss. 3, 2015-03 ,pp. : 323-330

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost Effectiveness of Interferon-Gamma Release Assay for Tuberculosis Screening of Rheumatoid Arthritis Patients prior to Initiation of Tumor Necrosis Factor-α Antagonist Therapy

By Kowada Akiko  

Molecular Diagnosis & Therapy, Vol. 14, Iss. 6, 2010-12 ,pp. : 367-373

Adis International

Access to resources Recommend Favorite

The risk of tuberculosis in patients with psoriasis treated with anti‐tumor necrosis factor agents

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : 594-599

John Wiley & Sons Inc

Access to resources Recommend Favorite

Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002

By Robinson Don   Hackett Monica   Wong John   Kimball Alexa B.   Cohen Russell   Bala Mohan    

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 989-1000

Informa Healthcare

Access to resources Recommend Favorite

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

By Sandborn W. J.   Colombel J.-F.   D’Haens G.   Plevy S. E.   Panés J.   Robinson A. M.   Pollack P. F.   Zhou Q.   Castillo M.   Thakkar R. B.  

Current Medical Research and Opinion, Vol. 29, Iss. 5, 2013-05 ,pp. : 483-493

Informa Healthcare

Access to resources Recommend Favorite